Literature DB >> 28478173

Carotid Body Tumors: A Case Series and Review of the Literature.

Youssef Darouassi1, Mustapha Alaoui2, Mohamed Mliha Touati3, Oussama Al Maghraoui2, Amine En-Nouali3, Brahim Bouaity3, Haddou Ammar3.   

Abstract

BACKGROUND: Paragangliomas of the head and neck are rare vascular tumors derived from the paraganglia tissues originating from the neural crest. They are usually benign and hypervascularized. Diagnosis is relatively easy in condition to consider it in evaluating every lateral neck mass.
METHODS: We made a retrospective study of the records of 10 patients who presented with carotid body tumors at the Department of Vascular surgery of the Military Hospital Avicenne in Marrakech during the period between 2008 and 2013. Epidemiologic, etiologic, diagnostic, and therapeutic features were analyzed.
RESULTS: The average age of our patients was 35.4 years (26-55 years), with a male predominance (sex ratio = 2.33). We noted 7 cases of isolated carotid locations and 3 cases of multiple locations. A slow-growing neck mass was the main clinical presentation. Other signs were pain, dysphonia, dizziness, headache, and tinnitus. Physical examination showed, in most cases, a neck nontender mass with side to side mobility. Imaging techniques included Doppler ultrasound, computed tomography (CT) scan, magnetic resonance imaging, and catheter arteriography. Urinary analysis for metanephrine was carried out in 1 case. The clinical presentation and imaging results strongly suggested the diagnosis of carotid paraganglioma in all cases. Treatment was surgical excision in all cases associated with a preoperative embolization in 1 case and a postoperative radiotherapy in 2 cases. Pathology confirmed the diagnosis, and a lymph node metastasis was suspected of malignity in 1 case. The evolution was favorable in all our patients.
CONCLUSIONS: Carotid body tumor requires early diagnosis and an adequate multidisciplinary team. The diagnosis must be considered in the case of any pulsatile cervical mass. Surgery is the treatment of choice despite its risks especially in large tumors. The therapeutic indication should, ideally, be set in a multidisciplinary consultation.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28478173     DOI: 10.1016/j.avsg.2017.03.167

Source DB:  PubMed          Journal:  Ann Vasc Surg        ISSN: 0890-5096            Impact factor:   1.466


  6 in total

1.  Clinical Characteristics and Surgical Outcomes of Carotid Body Tumors: Data from the Carotid Paraganglioma Cooperative International Registry (CAPACITY) Group.

Authors:  Mauricio Gonzalez-Urquijo; Victor Hugo Viteri-Pérez; Andrea Becerril-Gaitan; David Hinojosa-Gonzalez; María Elizabeth Enríquez-Vega; Ivan Walter Soto Vaca Guzmán; Gregorio Eloy Valda-Ameller; José de Jesús García-Pérez; Carlos Vaquero-Puerta; Victor Hugo Jaramillo-Vergara; Miguel Angel Cisneros-Tinoco; Joaquin Miguel Santoscoy-Ibarra; Mario Alejandro Fabiani
Journal:  World J Surg       Date:  2022-07-24       Impact factor: 3.282

2.  Carotid Body Tumor: Our Experience with 42 Patients and a Literature Review.

Authors:  Abbas Sarookhani; Rojin Chegini
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2021-02-23

3.  Carotid body tumor encounters over a two-decade period in an academic hospital.

Authors:  Abdulmajeed Altoijry; Hesham Alghofili; Kaisor Iqbal; Talal Altuwaijri; Badr Aljabri; Mussaad Al-Salman
Journal:  Medicine (Baltimore)       Date:  2022-10-14       Impact factor: 1.817

4.  Differential Diagnosis and Treatment Outcomes of Tumors at the Carotid Bifurcation.

Authors:  Jihee Kang; Seon-Hee Heo; Yang-Jin Park; Dong-Ik Kim; Young-Wook Kim
Journal:  Vasc Specialist Int       Date:  2020-09-30

5.  Carotid Body Tumor Microenvironment.

Authors:  Jean-Paul Bryant; Shelly Wang; Toba Niazi
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

6.  Cervical paragangliomas: experience of 114 cases in 14 years.

Authors:  Halil Basel; Nazim Bozan
Journal:  Braz J Otorhinolaryngol       Date:  2018-06-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.